MGI Aloxi Launch Set For September; Indications Include Delayed Nausea
Executive Summary
MGI Pharma plans to differentiate the antiemetic Aloxi (palonosetron) from other 5HT3 antagonists by highlighting a unique indication for delayed nausea in chemotherapy patients